Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a ...

Travere Therapeutics today announced the launch of a new awareness campaign, "Play It Forward," to bring hope and ...

The FDA launched a new Priority Review program, as uncertainty persists for the existing programme for paediatric disorders.

Travere Therapeutics (NASDAQ:TVTX), a biopharmaceutical company focused on developing therapies for rare diseases, finds itself at a critical juncture as it navigates regulatory challenges and ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Travere Therapeutics TVTX in the last three months. In the table below, you'll find a ...

Travere Therapeutics has turned music mogul, bringing together a singer-songwriter and Grammy-winning producer to create an ...

New data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of FILSPARI and its impact on B cell and complement pathways in IgAN Travere Therapeutics, Inc., (Nasdaq: TVTX) today ...

M.D., chief medical officer at Travere Therapeutics. “We are proud to support the FSGS community in amplifying individual expressions of life and courage, and we're committed to transforming the ...